行情

PGNX

PGNX

普罗基尼克斯制药
NASDAQ

实时行情|Nasdaq Last Sale

5.85
-0.05
-0.85%
盘后: 5.85 0 0.00% 16:31 11/14 EST
开盘
5.89
昨收
5.90
最高
5.93
最低
5.73
成交量
42.00万
成交额
--
52周最高
6.31
52周最低
3.420
市值
5.06亿
市盈率(TTM)
-6.9214
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PGNX 新闻

  • Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections
  • GlobeNewswire.6天前
  • Velan Receives Requisite Number Of Written Consents To Reconstitute Majority Of Progenics Board
  • Benzinga.6天前
  • Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board
  • Business Wire.6天前
  • Progenics Pharmaceuticals EPS beats by $0.04, misses on revenue
  • seekingalpha.11/07 18:10

更多

所属板块

生物技术和医学研究
-0.05%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

PGNX 简况

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
展开

Webull提供Progenics Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。